Research on Changes in Intestinal Barrier Function and Gut Microbiome in Patients With Type 2 Diabetes After Duodenal Mucosal Resurfacing (DMR)
- Disease/Condition
- Type 2 Diabetes Mellitus
- Drug/Device/Intervention
- DMR Procedure
- Study type
- Interventional
- Intervention type
- procedure
- Primary sponsor
- Wang Siqi
- Funder
- China-Japan Friendship Hospital
- Phase
- N/A
- Start date
- Jun 01, 2024
- End date
- Dec 01, 2025
- Enrollment
- 100 participants
Microbiome Analysis,High Performance Liquid Chromatography
The aim of this study is to demonstrate the effects of duodenal mucosal resurfacing (DMR) on
 intestinal barrier function and gut microbiota when treating uncontrolled type 2 diabetes.
 Subjects who underwent DMR and those who did not were enrolled, and potential differences
 were identified by analyzing urine and fecal samples through microbiotic analysis and High
 Performance Liquid Chromatography (HPLC), combined with changes in clinical data.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06385704
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06385704 through Pure Global AI's free database. This phase not specified trial is sponsored by Wang Siqi and is currently Not yet recruiting. The study focuses on Type 2 Diabetes Mellitus. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.